Monocenter, Randomized, Blinded, Intraindividual Study Evaluating Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D
Overview
- Phase
- Not Applicable
- Intervention
- Blue light treatment
- Conditions
- Psoriasis Vulgaris
- Sponsor
- Philips Electronics Nederland BV
- Enrollment
- 51
- Locations
- 1
- Primary Endpoint
- Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 30) as Compared to the VitaminD Treated Area (Control) at End of Treatment (Week 12).
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained.
At the baseline visit, all inclusion and exclusion criteria will be re-assessed. Eligible patients will be randomized to treatment of the target area with either 30 minutes (group30) or 15 minutes (group15) blue light at 600 milliwatt per square centimeter (mW/cm²). Additionally, two study areas with similar clinical symptomatology will be determined and will be randomized to blue light treated area and Daivonex (Vitamin D) treated area.
After randomization, patients will be trained on a demonstrator device (no actual treatment to ensure investigator is blinded as to which group the patient is randomized to) as well as the Daivonex cream. After patients have been instructed, treatment of the areas will be applied daily (once per day, 5-7 times / week) at home for a treatment period of 12 weeks. During those 12 weeks, patients will return to the study site for safety and effectiveness assessments at week 2, 4, 8 and week 12. A phone call visit will be performed after one week of treatment to check for any adverse events or problems in handling the device or the cream. The visit at week 12 serves as end of treatment visit. The patients will be followed-up for another 4 weeks. Treatment responses will be photo documented.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed and dated informed consent prior to any study-mandated procedure
- •Good health as determined by the Investigator
- •Willing and able to comply with study requirements
- •Skin type I-IV according to Fitzpatrick
- •Mild plaque-type psoriasis vulgaris with a Psoriasis Area and Severity Index (PASI) ≤ 10 and body surface area (BSA) ≤ 10 at screening.
- •Presence of two comparable psoriatic plaques suitable to be defined as study areas as follows:
- •located on extremities (plaques located on the palms or sole of the feet are not suitable)
- •Both areas located either on lower or upper extremity
- •Can be located on the same extremity
- •Distance between the two study areas ≥ 11cm (border to border)
Exclusion Criteria
- •Inmates of psychiatric wards, prisons, or other state institutions
- •Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
- •Participation in another clinical trial within the last 30 days
- •Pregnant or lactating women Medical History
- •Photodermatosis and/or Photosensitivity
- •Porphyria and/or hypersensitivity to porphyrins
- •Patients with current diagnosis of erythrodermic, exfoliative or pustular psoriasis
- •Congenital or acquired immunodeficiency
- •Patients with any of the following conditions present on the study areas: naevi or signs of hyperpigmentation, viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin
- •Patients with any of the following conditions present or who have been diagnosed in the past with any of the following conditions on the study areas: skin cancer, severe actinic damage and other precancerous lesions
Arms & Interventions
group30
Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
Intervention: Blue light treatment
group30
Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
Intervention: Vitamin D
group15
Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
Intervention: Blue light treatment
group15
Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
Intervention: Vitamin D
Outcomes
Primary Outcomes
Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 30) as Compared to the VitaminD Treated Area (Control) at End of Treatment (Week 12).
Time Frame: week 12
The local Psoriasis severity index (LPSI) was adapted from the well known PASI. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas (0-4). A total severity score was calculated as the sum of the three symptom ratings (range 0-12). The measure reported is the change in LPSI at end of treatment versus baseline. A negative change indicates an improvement of the LPSI.
Secondary Outcomes
- Change From Baseline in Patient Self-assessment of Severity of Psoriasis of the Blue Light Treated Area (Group 15) Compared to the VitaminD Treated (Control) Area at Week 12 (VAS Scale).(week 12)
- Lesional Erythema Measured by Mexameter Measured at End of Treatment.(week 12)
- Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 15) as Compared to the VitaminD Treated (Control) Area at End of Treatment (Week 12).(week 12)
- Change From Baseline in Patient Self-assessment of Severity of Psoriasis of the Blue Light Treated Area (Group 30) Compared to the VitaminD Treated (Control) Area at Week 12 (VAS Scale).(week 12)
- Patient Satisfaction (Week 12)(week 12)